Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep;28(9):1077-1081.
doi: 10.1017/S1047951118001014. Epub 2018 Jul 6.

Sacubitril/Valsartan: potential treatment for paediatric heart failure

Bibhuti B Das  1 , Frank Scholl  1 , Breanna Vandale  1 , Maryanne Chrisant  1
Affiliations
Review

Sacubitril/Valsartan: potential treatment for paediatric heart failure

Bibhuti B Das et al. Cardiol Young. 2018 Sep.

Abstract

The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure trial has demonstrated that Sacubitril/Valsartan is superior to Enalapril in reducing the risks of both sudden cardiac death and death from worsening heart failure. This novel combination, Sacubitril/Valsartan, is also shown to reduce the risk of hospitalisation and progression of heart failure in adults. However, the benefit of Sacubitril/Valsartan in paediatric heart failure patients is unknown. In this review, we discuss the similarities and differences in pathophysiology of heart failure in children versus adults, and the potential role of Sacubitril/Valsartan in paediatric heart failure patients.

Keywords: Paediatric heart failure; angiotensin receptor blocker; neprilysin inhibitor.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

LinkOut - more resources